LENSAR, Inc. LNSR
Medical/Dental Instruments · data as of November 13, 2026
LENSAR, Inc. (LNSR) is a healthcare company listed in the US with a market value of about $61M. In the twelve months to September 30, 2026 it had revenue of $60M and net income of $34M, a net margin of 56.1%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 1.8, 5-year revenue growth of 17% a year, a 5-year average ROIC of -50%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 4% above the current price.
About LENSAR
LENSAR is listed in the US and classified in medical/dental instruments. Revenue went from $31M in 2019 to $58M in 2025, growth of about 11.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 10% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $60M | $58M | $53M | $42M | $35M | $34M | $26M | $31M |
| Net income | $34M | -$34M | -$31M | -$14M | -$20M | -$20M | -$20M | -$15M |
| Free cash flow | -$5M | -$15M | -$2M | -$10M | -$15M | -$9M | -$14M | -$13M |
| EPS (diluted) | $2.72 | $-2.87 | $-2.73 | $-1.31 | $-1.96 | $-2.09 | $-4.28 | $-13.70 |
| Net margin | 56.1% | -58.7% | -58.7% | -34.1% | -56.3% | -56.9% | -75.0% | -48.0% |
| ROIC | — | — | -112.7% | -27.0% | -35.6% | -26.7% | -20.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is LENSAR’s P/E ratio?
About 1.8, based on the last twelve months of diluted earnings per share.
Is LENSAR stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 4% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does LENSAR pay a dividend?
Not currently.
Is LENSAR a good stock to buy?
We do not give buy or sell advice. LENSAR scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.